Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids

Higher global prevalence of non-alcoholic fatty liver disease (NAFLD) is associated with obesity, steatosis, and insulin resistance (IR), and often progresses to steatohepatitis (NASH). Even after more than twenty years of research, there is still no FDA approved therapy for the treatment of fatty l...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Soumalya Sarkar, Deepika Kumari, Sonu Kumar Gupta, Vipin Sharma, Sumedha Mukhi, Parul Kamboj, Vedula Sasibhushan, Rajiva Kumar Rai, Sastry Lakshminarayana Jatavallabhula, Dinesh Mahajan, Yashwant Kumar, Ajay Kumar, Madhu Dikshit
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	High fat high fructose Non-alcoholic fatty liver disease Insulin resistance Lipidomics Saroglitazar Hepano Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/34389400b90547f6a85e0882da0b10a7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids

Ejemplares similares